Skip to content
Catalyst

(-)-epigallocatechin 3-gallateFinding

(-)-epigallocatechin 3-gallate inhibits EGFR

lowersInsufficient evidenceFinding

01 · The sentence it was drawn from

“EGCG also suppressed EGFR expression, especially in Hep3BLR.”
Quoted verbatim from Antitumor Potential of Epigallocatechin Gallate in Overcoming Molecular Therapy Resistance in Hepatocellular Carcinoma.
This finding among the 1 finding on its endpoint

(-)-epigallocatechin 3-gallate

EGFR

inhibits

Who
Hep3B human hepatocellular carcinoma cells and the lenvatinib-resistant Hep3BLR subline
Dose studied
10 μg/ml

Insufficient evidencePMID 41006034 · 2025

02 · The study

Study
in vitro · not in humans
Duration
not reported

Evidence, by strength

  • strong
  • moderate
  • limited
  • very limited
  • insufficientthis finding

04 · To cite this finding

This address does not change

https://catalystproject.ai/e/01M3J952K7ZA0HWZ0GWP31FAPQ